Axys and Signal Enter Discovery Collaboration

Dec 17, 1998

Premium

SOUTH SAN FRANCISCO, Calif.--Axys Pharmaceuticals and Signal Pharmaceuticals announced they have entered into a collaboration for the accelerated discovery of compounds that interact with specific cell signaling pathways. Signal will use its proprietary assays to screen small molecules derived from Axys's compound libraries. Specific molecular targets were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Now You Can Read Them, Now You Can't

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

The Mouths of Heavy Drinkers Are Disgusting

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

For Health or For Fun?

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

This Week in Genome Research

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.

Jun

12

Featured Webinar

Bridging the Gap Between Testing and Treatment in Precision Oncology

This webinar will highlight a comprehensive end-to-end solution for precision care in oncology, comprising sample acquisition through to sequencing and analysis, treatment recommendations, and follow-through.

Main menu